Caliway's CBL-514 Meets Primary Endpoint in Phase 2 Dercum's Disease Trial, Pain Scores Fall 3.1 Points
核心洞察
Caliway Biopharmaceuticals (搜索) reported final Phase 2 CBL-0202DD results showing CBL-514 met its primary endpoint with a 3.1-point mean pain-score reduction at Week 20 versus 1.9 points for placebo (p=0.005).
Per-protocol analysis confirmed the same 3.1-point reduction against 1.4 points for placebo (p=0.0002), with secondary endpoints at Weeks 16 and 24 also reaching statistical significance.
Roughly 90% of CBL-514-treated patients achieved at least a 3-point pain reduction in more than half of their treated painful lipomas, and no drug-related serious adverse events were reported.
Caliway Biopharmaceuticals (搜索) reported on September 21 final statistical results from its randomized, single-blind, placebo-controlled Phase 2 trial CBL-0202DD, in which CBL-514 met its primary efficacy endpoint in Dercum's Disease (搜索), a rare disorder characterized by painful lipomas. The trial showed clinically meaningful and statistically significant pain reduction in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations, with benefits observed across multiple assessment time points and increasing over successive treatment courses.
Primary and Secondary Endpoints
The primary efficacy endpoint was assessed at Week 20. In the FAS population, patients treated with CBL-514 achieved a mean pain-score reduction of 3.1 points compared with 1.9 points in the placebo group, a statistically significant treatment effect (p=0.005). In the PP population, the same 3.1-point reduction compared against 1.4 points for placebo, with a p-value of 0.0002.
Secondary efficacy endpoints at Weeks 16 and 24 reinforced the primary result. In the FAS population, CBL-514 patients achieved mean pain-score reductions of 3.5 points and 4.1 points, respectively, versus 1.7 points at both time points for placebo (p=0.0017 and p<0.0001). In the PP population, the reductions were 3.5 points and 4.1 points against 1.2 points at both time points for placebo (p=0.0001 and p<0.0001).
The magnitude of response continued to increase through Week 24 rather than plateauing, which the company said supports the durability of the treatment effect. An exploratory analysis in the FAS population found that approximately 90% of CBL-514-treated patients achieved a clinically meaningful pain reduction of at least 3 points in more than half of their treated painful lipomas, markedly outperforming placebo.
Safety Profile
CBL-514 was generally well tolerated. No drug-related serious adverse events were reported. The most commonly reported treatment-emergent adverse events were mild-to-moderate local injection-site reactions, and the overall safety profile was consistent with expectations for ongoing clinical development.
Mechanism and Development Scope
CBL-514 is a patented, first-in-class small-molecule 505(b)(1) injection designed to selectively induce adipocyte apoptosis (搜索), reducing subcutaneous fat at the injection site without causing necrosis or damage to surrounding tissues or cells. A separate formulation, CBL-514D, is being developed specifically for Dercum's Disease (搜索).
Caliway said more than 544 subjects have participated in clinical trials related to CBL-514. Across 10 completed clinical trials with finalized statistical reports, all primary and key secondary efficacy endpoints have been met, according to the company. CBL-514 has also been studied in non-surgical subcutaneous fat reduction and moderate-to-severe cellulite.
Unmet Need in Dercum's Disease
Dercum's Disease (搜索) is a chronic, highly recurrent and debilitating rare disease marked by abnormal accumulation of subcutaneous adipose tissue in the trunk and extremities, producing painful lipomas or adipose masses. Patients frequently experience persistent pain lasting longer than three months, often with burning sensations and tenderness that can severely affect daily life. The exact cause and underlying pathophysiology remain incompletely understood, although growing evidence suggests abnormalities in adipose tissue metabolism may play a role.
No therapies are approved specifically for Dercum's Disease (搜索). Currently available approaches such as surgical removal provide only temporary symptomatic relief and are often associated with undesirable side effects. According to market research reports cited by the company, the global Dercum's Disease market was estimated at approximately US$11.3 billion in 2021 and is projected to reach approximately US$19.96 billion by 2030, a compound annual growth rate of approximately 6.76%.
Lipedema as a Follow-On Indication
Based on the CBL-0202DD results, Caliway said several key opinion leaders and potential pharmaceutical partners have recognized the therapeutic potential of CBL-514 in other adipose tissue disorders sharing clinical characteristics with Dercum's Disease (搜索), including lipedema (搜索). Lipedema predominantly affects women and is characterized by abnormal fat accumulation in the lower extremities and buttocks, frequently accompanied by pain, swelling and tenderness. Epidemiological and market research data suggest lipedema affects approximately 10% of women worldwide, a population the company links to a potential global market opportunity exceeding US$30 billion. No approved curative therapies exist for lipedema, and weight loss alone does not effectively address the underlying pathological fat accumulation.
Caliway said it plans to collaborate with clinical experts to evaluate the feasibility and clinical development strategy of CBL-514 in lipedema (搜索), leveraging the adipocyte apoptosis (搜索) mechanism to expand into additional indications with high unmet need.
Next Steps
The immediate question for the program is whether Caliway files for an end-of-Phase 2 meeting with the FDA in Dercum's Disease (搜索) before year end, since the design and scope of a Phase 3 trial will determine whether the Week 24 durability signal receives the longer follow-up needed to support a label claim.